Application of nometin in preparation of drug for ameliorating liver injury caused by cholestasis and metabolic diseases

A technology for metabolic diseases and liver damage, which can be used in drug combinations, pharmaceutical formulations, organic active ingredients, etc., and can solve the problems of complex pathogenesis of metabolic diseases.

Active Publication Date: 2018-11-23
SHANGHAI UNIV OF T C M
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the complex pathogenesis of metabolic diseases, the

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of nometin in preparation of drug for ameliorating liver injury caused by cholestasis and metabolic diseases
  • Application of nometin in preparation of drug for ameliorating liver injury caused by cholestasis and metabolic diseases
  • Application of nometin in preparation of drug for ameliorating liver injury caused by cholestasis and metabolic diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0126] animal model

[0127] High-fat diet-induced obese mice (DIO) experiment.

[0128] Mouse Modeling and Grouping

[0129] 7-week-old, C57BL / 6SPF female mice were acclimatized in the animal room for 1 week, and the Chow group was given a normal diet, and the rest were given a high-fat diet to induce obesity for 3 months. Finally, 30-40g obese mice that had been successfully modeled were selected, randomly divided into groups according to body weight, 8 mice in each group, and analyzed by SPSS21.0 software. There was no difference in body weight among the groups. Divided into: normal control group, high fat control group, high fat + obeticholic acid group, high fat + nomilin group.

[0130] Dosage and method of administration

[0131] Obeticholic acid: 15mg / kg Bodyweight / day (0.2 / 1000 high-fat feed)

[0132] Nomilin: 75mg / kg Bodyweight / day (1 / 1000 high-fat feed)

[0133] According to the above dosage, first mash the high-fat feed, then add the drug powder, mix well, and...

Embodiment 2

[0140] OB / OB Leptin Deficient Obese Mice Experiment

[0141] Mouse Modeling and Grouping

[0142] ob / ob mice, 12 weeks old, female, SPF level, weighing about 80g. All were given normal feed. According to the body weight, the rats were randomly divided into 6 groups, analyzed by SPSS21.0 software, and there was no difference in body weight among the groups. Divided into: normal group, ob / ob model group, ob / ob+nomilin (75mg / kg)

[0143] Dosage and method of administration

[0144] Gavage administration, once a day, continuously for one month, drug nomilin: 75 mg / kg, dissolved in 0.5% CMCNa, and ultrasonically prepared into a suspension in an ultrasonic instrument.

[0145] Effects of nomilin on the liver of ob / ob mice

[0146] Pathological analysis of liver HE staining in ob / ob mice: Compared with normal mice, the liver fatty degeneration of mice in the model group was very serious, and vacuolar deformation appeared (HE staining of ob / ob mouse liver and the content of liver...

Embodiment 3

[0148] MCD feed-induced steatohepatitis (NASH) mice experiment

[0149] Mouse Modeling and Grouping

[0150] 7-week-old, C57BL / 6SPF female mice were fed to 20-25g in the animal room of Shanghai University of Traditional Chinese Medicine. After the normal group was given MCS feed, the rest were all fed MCD feed. After 3 weeks of modeling, they were randomly divided into groups according to body weight. Eight rats in each group were analyzed by SPSS21.0 software, and there was no difference in body weight among the groups. Divided into: MCS control group, MCD model group, obeticholic acid group, nomilin (75mg / kg).

[0151] Dosage and method of administration

[0152] Gavage administration, once a day, continuous gavage for 4 weeks. Nomilin: 75mg / kg, dissolved in 0.5% CMCNa, and made into a suspension by sonication.

[0153] Nomilin ameliorates hepatic steatosis in mice induced by MCD diet

[0154] In order to further study the therapeutic effect of nomilin on alcoholic fatt...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of noremin in preparation of a drug for ameliorating liver injury caused by cholestasis and metabolic diseases, and belongs to the technical field of drug preparation. According to the application of the nometin in preparation of the drug for ameliorating the liver injury caused by the echolestasis and the metabolic diseases, the noremin can achieve an obviousamelioration effect on the liver injury by improving bile acid metabolism, anti-inflammatory and anti-oxidative stress, reducing lipid synthesis and the like.

Description

technical field [0001] The invention relates to the technical field of medicine preparation, in particular to the application of nomilin in the preparation of medicines for improving liver damage caused by cholestasis and metabolic diseases. Background technique [0002] With the development of society and economy, people's living standard and dietary structure change, the incidence of metabolic diseases is increasing day by day, such as obesity, diabetes, insulin resistance, hypertension, hyperlipidemia, etc. The liver is an important organ that regulates the metabolism of sugar, fat, protein, and bile acids in the body, and is also the central organ that maintains homeostasis. If the liver is damaged, the vitality of liver cells will decrease, the detoxification function will be weakened, and the sensitivity to damage factors such as oxidative stress will increase, which will further lead to inflammation and fibrosis. Liver damage caused by metabolic diseases is mainly ma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/585A61P1/16
CPCA61K31/585A61P1/16
Inventor 黄诚范圣洁骆玲玲曹禹李鸿丽李俊晓方金安
Owner SHANGHAI UNIV OF T C M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap